The Limits of the P-Value in Peptide Research
For decades, the p-value has served as the primary gatekeeper of scientific credibility in biomedical research. A result crossing the threshold of p < 0.05 has been treated, in practice, as evidence that a finding is real and meaningful. In peptide pharmacology, where preclinical studies routinely guide decisions about synthesis investment, animal model selection, and eventual clinical translation, this reliance on a single threshold statistic carries measurable risk.
The American Statistical Association addressed this directly in its 2016 statement on p-values, noting that the p-value cannot tell a researcher whether a hypothesis is true, whether an effect is large enough to matter, or whether a study was adequately designed to detect the effect in question [2]. A p-value of 0.03 in a receptor binding assay confirms only that the observed result would be unlikely under the null hypothesis — it says nothing about the magnitude of the effect, the precision of the estimate, or the probability that the finding will replicate.
For researchers evaluating peptide preclinical data, two complementary tools address these gaps: confidence intervals (CIs) and effect size statistics. Together, they shift the interpretive frame from binary significance testing toward a richer, more informative picture of biological meaningfulness.
Statistical Significance Versus Biological Significance
The distinction between statistical and biological significance is not merely semantic. A study with a very large sample size can achieve p < 0.001 for an effect so small it has no plausible relevance to the underlying biology. Conversely, a small pilot study may produce a wide CI that crosses the null — technically non-significant — while still suggesting a biologically plausible and potentially important effect worth investigating further.
Consider a peptide receptor binding assay reporting an EC50 of 12 nM versus a reference compound at 15 nM, with p = 0.04. The statistical significance is present, but the 20% difference in potency, if confirmed by a narrow CI, may not justify the compound's development over the reference. The p-value alone does not communicate this. Reporting the 95% CI around each EC50 estimate — say, 10–14 nM versus 11–19 nM — immediately reveals both the magnitude of the difference and the relative precision of each measurement.
Nakagawa and Cuthill, writing specifically for biologists, articulate this principle clearly: effect sizes and CIs should be reported alongside or in place of p-values in all experimental biology, because they provide the information actually needed to assess whether a finding is worth acting upon [7].
Understanding Confidence Intervals as Precision Markers
A 95% confidence interval is best understood as a range of plausible values for the true population parameter, constructed such that 95% of identically designed studies would produce intervals containing the true value [1]. In practical terms, a narrow CI indicates that the study has produced a precise estimate; a wide CI signals substantial uncertainty, regardless of whether the result crosses a significance threshold.
In peptide pharmacology, CI width is directly informative about study quality and sample adequacy. A GLP-1 receptor agonist preclinical study reporting a mean body weight reduction of 8% with a 95% CI of 6.5–9.5% in a rodent model is communicating something qualitatively different from a study reporting the same 8% mean with a CI of 1–15%. The first study provides a reliable estimate; the second suggests the true effect could be trivially small or remarkably large — a distinction that matters enormously when deciding whether to advance a compound.
Wide CIs in peptide studies most commonly arise from small sample sizes, high biological variability between animals or preparations, or inconsistent assay conditions. They are not a failure of the science per se, but they are a marker of uncertainty that must be weighed explicitly when interpreting results.
The Paradox of Significant but Imprecise Results
One of the more counterintuitive features of frequentist statistics is that a result can be both statistically significant and highly imprecise. This occurs when the lower bound of a wide CI still excludes the null value. A peptide study might report p = 0.04 with a 95% CI for the effect on receptor occupancy spanning 1–40 percentage points. The result is technically significant, but the CI width reveals that the study cannot reliably distinguish between a clinically negligible effect and a substantial one.
Recognising this pattern is a critical skill for anyone evaluating peptide preclinical literature. Statistical significance, in such cases, is not a licence to conclude that the effect is meaningful — it is an invitation to conduct a better-powered study.
Effect Size Statistics: Definitions and Applications
Effect size statistics quantify the magnitude of an observed difference or relationship, independent of sample size. Three measures are particularly relevant to peptide research contexts.
Cohen's d and Hedges' g
Cohen's d expresses the difference between two group means in units of the pooled standard deviation [3]. In a peptide efficacy study comparing treated and control animals, a d of 0.2 is conventionally described as small, 0.5 as medium, and 0.8 as large — though these benchmarks are context-dependent and should not be applied mechanically to biological data.
Hedges' g is a corrected version of Cohen's d that adjusts for bias introduced by small sample sizes, making it preferable in most preclinical peptide studies where group sizes are typically modest [7]. The correction is particularly important in studies with fewer than 20 animals per group, where Cohen's d systematically overestimates the true population effect.
In practice, a peptide weight-loss study reporting Hedges' g = 0.9 with a 95% CI of 0.5–1.3 is providing substantially more actionable information than one reporting only p = 0.001. The effect size indicates a large and consistent difference; the CI confirms the estimate is reasonably precise.
Eta-Squared and Partial Eta-Squared
Eta-squared (η²) is appropriate when the research question involves more than two groups or a factorial design — common in dose-response studies where multiple peptide concentrations are compared simultaneously. It expresses the proportion of total variance in the outcome that is attributable to the treatment [3].
In a receptor binding assay examining four concentrations of a novel peptide, η² = 0.45 would indicate that 45% of the variance in binding affinity is explained by concentration — a large effect by most standards. Partial eta-squared isolates the variance attributable to a single factor in a multi-factor design, making it useful when studies include covariates such as animal weight or baseline receptor expression.
Common Reporting Pitfalls in Peptide Literature
Several patterns of incomplete or misleading statistical reporting recur in the peptide preclinical literature and deserve specific attention.
Selective P-Value Reporting
Studies that report p-values for statistically significant outcomes while omitting CIs and effect sizes create a systematically distorted picture of the evidence base. Without knowing the magnitude and precision of effects, it is impossible to conduct meaningful comparisons across studies or to assess whether a compound's preclinical profile is consistent enough to support clinical translation.
The practical consequence is that a researcher reviewing five studies on a peptide's effect on a metabolic endpoint may encounter five p-values below 0.05 and conclude the evidence is robust — when in fact the underlying effect sizes vary from trivially small to moderately large, and the CIs are wide enough to be consistent with near-zero effects in some studies.
Failure to Report Baseline Variance
Effect size calculations depend on variance estimates, and baseline variance in peptide studies — particularly in vivo models — can differ substantially across laboratories, animal strains, and housing conditions. A study that reports only means and p-values without standard deviations or standard errors makes it impossible for readers to calculate effect sizes independently or to assess whether the reported CI is plausible given the experimental design.
Post-Hoc Power Analysis Misuse
Post-hoc power analysis — calculating statistical power after a study has been completed, using the observed effect size — is a widely misunderstood practice. When a study produces a non-significant result, researchers sometimes calculate post-hoc power to argue that the study was underpowered. This reasoning is circular: observed power is a direct mathematical transformation of the p-value and provides no independent information about whether the study was adequate [2].
The correct application of power analysis is prospective, using effect sizes derived from prior literature or mechanistic reasoning to determine the sample size needed before data collection begins. In peptide research, where animal studies are resource-intensive and ethically constrained, prospective power planning is both scientifically and practically essential.
Sample Size, Power, and the Inflation of Preclinical Effect Sizes
Underpowered studies — those with insufficient sample sizes to reliably detect the true effect — produce systematically inflated effect size estimates when they achieve statistical significance. This phenomenon, sometimes called the winner's curse, arises because small studies can only reach significance when the observed effect happens to be larger than the true effect by chance [6].
In the peptide preclinical literature, where group sizes of five to ten animals are common, this inflation can be substantial. A study with n = 6 per group that reports a statistically significant effect with Hedges' g = 1.2 should be interpreted with caution: the true effect may be considerably smaller, and the wide CI that accompanies such a study — if reported — will typically confirm this uncertainty.
This has direct implications for meta-analytic thinking. When reviewing multiple small peptide studies, the largest reported effect sizes are often the least reliable. A more conservative approach weights estimates by their precision, giving greater credence to studies with narrow CIs even when those CIs correspond to more modest effect sizes.
Comparing Across Studies: Meta-Analytic Thinking
One of the most valuable applications of effect size reporting is the ability to compare findings across studies — an informal meta-analytic approach that does not require formal pooling of data. When multiple preclinical peptide studies report Hedges' g or η² alongside CIs, a researcher can visually assess whether effects are consistent in magnitude and direction, or whether they vary in ways that suggest moderating variables such as species, dose, or assay format.
Cumming describes this as thinking in terms of an accumulated evidence base rather than isolated binary decisions [1]. A series of studies on a GLP-1 analogue's effect on food intake in rodent models, each reporting effect sizes between 0.6 and 1.0 with reasonably narrow CIs, provides a much stronger basis for development confidence than five studies each reporting only p < 0.05.
This approach also helps identify outliers — studies with effect sizes dramatically larger or smaller than the rest of the literature — which may reflect methodological differences, publication bias, or genuine biological heterogeneity worth investigating.
Bayesian Alternatives: Credible Intervals and Posterior Distributions
Frequentist CIs, while widely used, carry a subtle interpretive constraint: they describe the behaviour of the estimation procedure across hypothetical repeated samples, not the probability that the true parameter lies within the interval for any given study. This distinction matters when interpreting single studies, as is typically the case in early-stage peptide research.
Bayesian credible intervals offer a more direct interpretation: given the observed data and prior information, there is a 95% probability that the true parameter lies within the credible interval. This framing is often more intuitive for researchers making decisions about whether to invest in further development [5].
Kruschke and Liddell argue that Bayesian estimation — which produces a full posterior distribution over possible effect sizes rather than a single point estimate — is particularly well-suited to the iterative, evidence-accumulating nature of early-stage research [5]. In peptide pharmacology, where each study informs the design of the next, the ability to formally incorporate prior evidence into the analysis has practical value.
Neither frequentist nor Bayesian approaches are universally superior; the choice depends on the research context, available prior information, and the interpretive needs of the audience. What both approaches share is an emphasis on estimation and uncertainty quantification over binary significance testing — a shift that benefits the field regardless of the statistical framework adopted.
Practical Guidance for Evaluating Peptide Preclinical Data
When assessing a peptide preclinical study, several questions provide a structured framework for moving beyond p-value interpretation.
First, does the study report an effect size alongside the p-value? If not, can one be calculated from the reported means and standard deviations? A study that provides sufficient data for independent effect size calculation is more transparent than one that does not.
Second, what is the width of the reported CI relative to the magnitude of the effect? A CI that spans a range from clinically negligible to clinically important is not providing the precision needed to make development decisions, regardless of its statistical significance.
Third, how does the reported effect size compare to other studies on similar peptide classes or endpoints? An effect size that is dramatically larger than the literature average warrants scepticism, particularly if it comes from a small study.
Finally, was the sample size determined prospectively based on a plausible effect size estimate, or does the study appear underpowered? Post-hoc power calculations should be treated with caution; prospective power planning, documented in the methods, is the more credible standard.
Applying these questions consistently does not guarantee correct conclusions — biological complexity ensures that uncertainty will always remain. But it does ensure that the evidence is being evaluated on its actual informational content rather than on the presence or absence of a single threshold statistic.